Article (Scientific journals)
Phenotypical characterization of alpha-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
De Brabander, Isabel; Yperzeele, Laetitia; Ceuterick-De Groote, Chantal et al.
2013In Clinical Neurology and Neurosurgery, 115 (7)
Peer Reviewed verified by ORBi
 

Files


Full Text
CNN.Fabry.article.pdf
Publisher postprint (242.55 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] OBJECTIVE: In the Belgian Fabry Study (BeFaS), the prevalence of Fabry disease was assessed in 1000 young patients presenting with stroke, unexplained white matter lesions or vertebrobasilar dolichoectasia. The results of the BeFaS suggested that Fabry disease may play a role in up to 1% of young patients presenting with cerebrovascular disease. However, the clinical relevance was unclear in all cases. We report on detailed phenotyping in subjects identified with alpha-galactosidase A (alpha-Gal A) enzyme deficiency or GLA mutations identified in the BeFaS (n=10), and on the results of family screening in this population. METHODS: Family screening was performed to identify additional mutation carriers. Biochemical and/or clinical evaluation of all subjects (BeFaS index patients and relatives carrying a GLA mutation) was performed. RESULTS: Genetic family screening revealed 18 additional GLA mutation carriers. Bloodspot alpha-Gal A enzyme activity was normal in all GLA mutation carriers, even in 2 males with the p.A143T mutation. Plasma Gb3 and lyso-Gb3 levels were normal in all subjects. Elevated Gb3 in urine was detected in 2 subjects. Some classic clinical signs of Fabry disease, like angiokeratoma or cornea verticillata, could not be detected in our population. Cardiac symptoms of Fabry disease were found in 6 out of 10 p.A143T carriers. No signs of cerebrovascular disease were found in the relatives with a GLA mutation. CONCLUSIONS: We could not identify mutations causing the classical clinical phenotype of Fabry disease in our cerebrovascular disease population. Enzyme activity analysis in bloodspots and plasma may fail to identify late-onset variants of Fabry disease. We recommend genetic testing when an atypical, late-onset variant of Fabry disease is suspected in a male cerebrovascular disease patient. However, this may lead to the identification of non-disease causing or controversial genetic variants.
Disciplines :
Neurology
Author, co-author :
De Brabander, Isabel
Yperzeele, Laetitia
Ceuterick-De Groote, Chantal
Brouns, Raf
Baker, Robert
Belachew, Shibeshih ;  Université de Liège - ULiège > Département des sciences cliniques > Neurologie
Delbecq, Jean
De Keulenaer, Gilles
Dethy, Sophie
Eyskens, Francois
Fumal, Arnaud
Hemelsoet, Dimitri
Hughes, Derralynn
Jeangette, Sandrine
Nuytten, Dirk
Redondo, Patricia
Sadzot, Bernard ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Sindic, Christian
Sheorajpanday, Rishi
Thijs, Vincent
Van Broeckhoven, Christine
De Deyn, Peter P.
More authors (12 more) Less
Language :
English
Title :
Phenotypical characterization of alpha-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
Publication date :
2013
Journal title :
Clinical Neurology and Neurosurgery
ISSN :
0303-8467
eISSN :
1872-6968
Publisher :
Elsevier, Netherlands
Volume :
115
Issue :
7
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2012 Elsevier B.V. All rights reserved.
Available on ORBi :
since 15 December 2012

Statistics


Number of views
110 (4 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
30
Scopus citations®
without self-citations
28
OpenCitations
 
28

Bibliography


Similar publications



Contact ORBi